Clinical trials: HIV Disease
HIV, Pediatric
Safety Sudy of Atazanavir Boosted With Ritonavir in the Treatment of HIV Infection in Pediatric Patients
The purpose of this study is to collect safety clinical data in HIV-infected pediatric patients aged 6 and older to younger than18 years and weighing 15 kg or more, who are receiving atazanavir capsule boosted with ritonavir and…
- Trial name
- NCT01691794
- Testing
- Atazanavir, Ritonavir
- Where
- 27 sites in United States, Argentina and 6 more
- Volunteers
- 108 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects
The objectives of this study are to explore the metabolic toxicities associated with lopinavir/ritonavir (LPV/r) plus saquinavir mesylate (INV) versus LPV/r plus Combivir in antiretroviral naïve subjects and to assess the overall…
- Trial name
- NCT00043953
- Testing
- Lopinavir/ritonavir, Saquinavir mesylate, Lamivudine/zidovudine
- Where
- 11 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Abbott
Anemia, Acquired Immunodeficiency Syndrome
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their Disease
The purpose of this study is to evaluate the effectiveness and safety of epoetin alfa versus placebo for the treatment of anemia in AIDS (Acquired Immunodeficiency Syndrome) patients with anemia that is a result of this disease…
- Trial name
- NCT00269945
- Testing
- epoetin alfa
- Volunteers
- 60 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hepatitis C, Chronic
Phase III Trial of BI 201335 (Faldaprevir) in Treatment Naive (TN) and Relapser Hepatitis C Virus (HCV)-Human Immunodeficiency Virus (HIV) Coinfected Patients (STARTverso 4)
the aim of this trial is to evaluate the efficacy and the safety of BI 201335 given for 12 or 24 weeks in combination with PegIFN/RBV given for 24-48 weeks, according to re-randomisation of Early Treatment Success (ETS) patients…
- Trial name
- NCT01399619
- Testing
- PegIFN/RBV, BI201335, BI201335 24W
- Where
- 71 sites in United States, Brazil and 6 more
- Volunteers
- 310 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Gastrointestinal Diseases
Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease
PRIMARY: To compare the frequency of and time to relapse of Cytomegalovirus (CMV) gastrointestinal disease following foscarnet induction therapy only versus induction plus maintenance therapy.
- Trial name
- NCT00002145
- Testing
- Foscarnet sodium
- Where
- 15 sites in United States
- Volunteers
- 145 people
- Sponsor
- Astra USA
HIV Infections
Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection
This is an open-label, randomized and multi-center study to compare the efficacy and safety of continued enfuvirtide (Fuzeon) plus (+) OB therapy versus OB alone in participants with HIV-1 infection.
- Trial name
- NCT02733419
- Testing
- Enfuvirtide, Optimized background antiretroviral regimen (OB)
- Where
- 71 sites in France
- Volunteers
- 84 people
- Sponsor
- Hoffmann-La Roche
HIV-1 Infection, HIV Infections
Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants
DNA vaccines consist of small pieces of DNA also known as plasmids, and have several potential advantages over traditional vaccines. Thus far, DNA vaccines appear to be well tolerated in humans.
- Trial name
- HIV-001 (NCT01082692)
- Testing
- PENNVAX-B
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Inovio Pharmaceuticals
Human Immunodeficiency Virus (HIV)
Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)
This study will evaluate how safe Budigalimab is and how it moves within the body in adult participants with HIV-1 infection. Budigalimab is an investigational drug being evaluated for the treatment of Human Immunodeficiency…
- Trial name
- NCT04799353
- Testing
- Budigalimab
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 33 people
- Sponsor
- AbbVie
HIV Infections
An Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of Dideoxycytidine (ddC) in Patients With AIDS or Advanced ARC Who Previously Demonstrated Intolerance to Zidovudine (AZT) in Protocol N3300 or N3492
To demonstrate that zalcitabine (dideoxycytidine; ddC) monotherapy is safe and tolerable in the treatment of patients with AIDS or advanced AIDS related complex (ARC) who previously demonstrated intolerance to zidovudine (AZT)…
- Trial name
- NCT00002265
- Testing
- Zalcitabine
- Where
- 9 sites in United States
- Sponsor
- Hoffmann-La Roche
Infection, Human Immunodeficiency Virus
A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)
This study is designed to compare the efficacy and safety of simplifying therapy from a regimen of atazanavir (ATV) + ritonavir (RTV) + tenofovir/emtricitabine (TDF/FTC) to a regimen of ATV + abacavir sulfate/lamivudine (ABC/3TC)…
- Trial name
- ASSURE (NCT01102972)
- Testing
- Reyataz + Norvir + Truvada, Reyataz + Epzicom
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 297 people
- Sponsor
- ViiV Healthcare
HIV Infections
Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir
Study ING116529 is a multicenter, randomized, study with an initial 7 day placebo- controlled, functional monotherapy phase to quantify the antiviral activity attributable to dolutegravir (DTG) in HIV-1 infected, ART-experienced…
- Trial name
- VIKING-4 (NCT01568892)
- Testing
- Dolutegravir 50 mg twice daily
- Where
- 25 sites in United States
- Volunteers
- 30 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Long Term Safety Study of Apricitabine in HIV-infected Patients
This study will examine the long term safety of apricitabine in HIV-1 infected patients from studies AVX-301 or AVX-302. Eligible patients are those who have either (a)completed studies AVX-301 or AVX-302; or (b)met the criteria…
- Trial name
- NCT00686270
- Testing
- apricitabine
- Sponsor
- Avexa
HIV Infections
An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml
To provide product through an expanded access program to HIV-infected patients with CD4 counts less than 300 cells/ml.
- Trial name
- NCT00002172
- Testing
- HIV-1 Immunogen
- Where
- United States
- Sponsor
- The Immune Response Corporation
Meningitis, Cryptococcal, HIV Infections
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.
- Trial name
- NCT00002305
- Testing
- Flucytosine, Fluconazole, Amphotericin B
- Where
- 45 sites in United States, Canada
- Sponsor
- Pfizer
HIV Infection
Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score
The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.
- Trial name
- NCT00234975
- Testing
- Lopinavir/Ritonavir
- Where
- 11 sites in Puerto Rico
- Volunteers
- 86 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89
To assess the safety of single oral doses of 1592U89 (abacavir succinate, ABC) administered to HIV-positive individuals. To determine the pharmacokinetics of 1592U89 after single oral doses.
- Trial name
- NCT00002141
- Testing
- Abacavir sulfate
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Burroughs Wellcome
AIDS Dementia Complex, HIV Infections
A Phase III, Randomized, Double-Blind, Multicentre Study to Evaluate the Safety and Efficacy of 1592U89 in Patients With AIDS Dementia Complex
To evaluate the benefit of adding 1592U89 to current antiretroviral therapies for AIDS dementia complex and to assess the safety and tolerance of the treatment regimens.
- Trial name
- NCT00002163
- Testing
- Abacavir sulfate
- Where
- 9 sites in United States, Canada
- Sponsor
- Glaxo Wellcome
HIV Prevention
To Assess Continued Safety of and Adherence to the Dapivirine (25 mg) Vaginal Ring-004 in Healthy, HIV-negative Women
A follow-on, open label trial to assess continued safety of and adherence to the Dapivirine(25mg) vaginal ring-004 in healthy, HIV-negative women
- Trial name
- NCT02862171
- Testing
- Dapivirine Vaginal Ring-004
- Where
- 6 sites in South Africa, Uganda
- Volunteers
- 941 people, healthy volunteers welcome
- Sponsor
- International Partnership for Microbicides, Inc.
HIV Infections
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
The study aims at evaluating the efficacy of VH3810109, dosed in accordance with the dosing schedule as either intravenous (IV) infusion or subcutaneous (SC) infusion with recombinant hyaluronidase (rHuPH20), in combination with…
- Trial name
- EMBRACE (NCT05996471)
- Testing
- VH3810109, Cabotegravir, Standard of care (SOC)
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 185 people
- Sponsor
- ViiV Healthcare
Cryptosporidiosis, HIV Infections
Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients
The purpose of this study is to see if it is safe and effective to treat cryptosporidiosis in AIDS patients with nitazoxanide.
- Trial name
- NCT00004986
- Testing
- Nitazoxanide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Romark Laboratories L.C.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.